Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Genscript Biotech Corp (OP: GNNSF ) 1.535 UNCHANGED Streaming Delayed Price Updated: 1:35 PM EDT, Oct 31, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Genscript Biotech Corp Will Genscript Cash Out Of Legend Biotech In The Face Of Fat Profit Temptation? August 01, 2024 Key Takeaways: Analysts expect annual sales of Carvykti, Legend Biotech’s core cancer therapy, to peak at $7.3 billion With about $2 billion in cash reserves, Genscript isn’t under pressure to sell its... Via Benzinga Week In Review: Korea's SK Biopharma Acquires Radiopharmaceutical In $571 Million Deal July 20, 2024 In recent news, South Korea’s SK Biopharma in-licensed global rights to a radiopharmaceutical compound developed by Full-Life Technologies of Shanghai in a $571 million deal. Via Talk Markets Week In Review: Structure Reports Efficacy Of Obesity Drug; Raises $476 Million June 08, 2024 Structure Therapeutics announced positive clinical results for its obesity drug, and then raised $476 million via an offering of its ADSs. Meanwhile, Alphamab Oncology announced a deal with ArriVent... Via Talk Markets 3 DNA Stocks to Buy for the Synthetic Biology Revolution May 14, 2023 Synthetic biology is a growing industry. The big winners will be DNA stocks that are able to sell to everyone, not just a small niche. Via InvestorPlace The Next Big Disruptors? 3 Biotech Stocks Making Headlines. February 17, 2023 Biotech stocks were hard-hit in 2022, but these disruptive names in the field of synthetic biology can be big winners in 2023. Via InvestorPlace Week In Review: Mabwell Out-Licenses Rare Disease Drug For $412.5 Million January 21, 2023 Mabwell Biosciences out-licensed global rights for a rare disease drug to Disc Medicine of Cambridge, MA in a $412.5 million agreement. Mabwell will receive $10 million upfront, $402.5 million in... Via Talk Markets Three Pharma Stocks to Sell Before They Die December 24, 2022 As we head into New Year 2023, these are just some of the top pharma stocks to sell at the start of January. Via InvestorPlace Week In Review: Akeso Out-Licenses PD-1/VEGF To Summit In $5 Billion Pact December 10, 2022 In a blockbuster agreement, Guangzhou’s Akeso out-licensed ex-China rights to its bispecific PD-1/VEGF candidate in a deal worth up to $5 billion. Summit Therapeutics will pay $500 million upfront and... Via Talk Markets Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
